POLE proofreading mutation, immune response and prognosis in endometrial cancer

Endometrial cancers (ECs) with POLE proofreading mutations are typified by ultramutation and excellent prognosis. We investigated whether these were related, and found that POLE-mutant ECs display a robust T cell response that corresponds to an enrichment of antigenic tumor neopeptides. Enhanced imm...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gool, Inge C., Bosse, Tjalling, Church, David N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839358/
https://www.ncbi.nlm.nih.gov/pubmed/27141333
http://dx.doi.org/10.1080/2162402X.2015.1072675
_version_ 1782428128037044224
author van Gool, Inge C.
Bosse, Tjalling
Church, David N.
author_facet van Gool, Inge C.
Bosse, Tjalling
Church, David N.
author_sort van Gool, Inge C.
collection PubMed
description Endometrial cancers (ECs) with POLE proofreading mutations are typified by ultramutation and excellent prognosis. We investigated whether these were related, and found that POLE-mutant ECs display a robust T cell response that corresponds to an enrichment of antigenic tumor neopeptides. Enhanced immunogenicity may explain the favorable outcome of POLE-mutant ECs.
format Online
Article
Text
id pubmed-4839358
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48393582016-05-02 POLE proofreading mutation, immune response and prognosis in endometrial cancer van Gool, Inge C. Bosse, Tjalling Church, David N. Oncoimmunology Author's View Endometrial cancers (ECs) with POLE proofreading mutations are typified by ultramutation and excellent prognosis. We investigated whether these were related, and found that POLE-mutant ECs display a robust T cell response that corresponds to an enrichment of antigenic tumor neopeptides. Enhanced immunogenicity may explain the favorable outcome of POLE-mutant ECs. Taylor & Francis 2015-08-12 /pmc/articles/PMC4839358/ /pubmed/27141333 http://dx.doi.org/10.1080/2162402X.2015.1072675 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
van Gool, Inge C.
Bosse, Tjalling
Church, David N.
POLE proofreading mutation, immune response and prognosis in endometrial cancer
title POLE proofreading mutation, immune response and prognosis in endometrial cancer
title_full POLE proofreading mutation, immune response and prognosis in endometrial cancer
title_fullStr POLE proofreading mutation, immune response and prognosis in endometrial cancer
title_full_unstemmed POLE proofreading mutation, immune response and prognosis in endometrial cancer
title_short POLE proofreading mutation, immune response and prognosis in endometrial cancer
title_sort pole proofreading mutation, immune response and prognosis in endometrial cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839358/
https://www.ncbi.nlm.nih.gov/pubmed/27141333
http://dx.doi.org/10.1080/2162402X.2015.1072675
work_keys_str_mv AT vangoolingec poleproofreadingmutationimmuneresponseandprognosisinendometrialcancer
AT bossetjalling poleproofreadingmutationimmuneresponseandprognosisinendometrialcancer
AT churchdavidn poleproofreadingmutationimmuneresponseandprognosisinendometrialcancer

Ejemplares similares